KR102191432B1 - Lactobacillus taiwanensis strain having antibacterial activity against harmful bacteria and uses thereof - Google Patents
Lactobacillus taiwanensis strain having antibacterial activity against harmful bacteria and uses thereof Download PDFInfo
- Publication number
- KR102191432B1 KR102191432B1 KR1020190060484A KR20190060484A KR102191432B1 KR 102191432 B1 KR102191432 B1 KR 102191432B1 KR 1020190060484 A KR1020190060484 A KR 1020190060484A KR 20190060484 A KR20190060484 A KR 20190060484A KR 102191432 B1 KR102191432 B1 KR 102191432B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- genus
- lactobacillus
- salmonella
- streptococcus
- Prior art date
Links
- 241000390527 Lactobacillus taiwanensis Species 0.000 title claims abstract description 60
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 56
- 241000894006 Bacteria Species 0.000 title abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 26
- 230000036541 health Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 241000193755 Bacillus cereus Species 0.000 claims description 25
- 241000186660 Lactobacillus Species 0.000 claims description 23
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 claims description 22
- 229940039696 lactobacillus Drugs 0.000 claims description 22
- 241000235070 Saccharomyces Species 0.000 claims description 21
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 241000607142 Salmonella Species 0.000 claims description 18
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- 241000194056 Streptococcus iniae Species 0.000 claims description 16
- 235000021107 fermented food Nutrition 0.000 claims description 16
- 241000194017 Streptococcus Species 0.000 claims description 13
- 239000007858 starting material Substances 0.000 claims description 13
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 244000052769 pathogen Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims description 10
- 241000588722 Escherichia Species 0.000 claims description 10
- 241000488157 Escherichia sp. Species 0.000 claims description 9
- 241000235088 Saccharomyces sp. Species 0.000 claims description 9
- 241000607149 Salmonella sp. Species 0.000 claims description 9
- 241000194022 Streptococcus sp. Species 0.000 claims description 9
- 239000003674 animal food additive Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 235000019249 food preservative Nutrition 0.000 claims description 5
- 239000005452 food preservative Substances 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 8
- 208000035143 Bacterial infection Diseases 0.000 abstract description 7
- 239000003755 preservative agent Substances 0.000 abstract description 6
- 230000000843 anti-fungal effect Effects 0.000 abstract description 5
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 5
- 230000002335 preservative effect Effects 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- 239000012228 culture supernatant Substances 0.000 description 17
- 239000004310 lactic acid Substances 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 13
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 13
- 108010062877 Bacteriocins Proteins 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 244000005700 microbiome Species 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 240000001817 Cereus hexagonus Species 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010067770 Endopeptidase K Proteins 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002032 methanolic fraction Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 244000205754 Colocasia esculenta Species 0.000 description 4
- 235000006481 Colocasia esculenta Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 229940077731 carbohydrate nutrients Drugs 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000002072 anti-mutant effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 208000010824 fish disease Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/34635—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3571—Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A23Y2220/00—
-
- C12R1/225—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 항균 및 항진균 활성을 갖는 락토바실러스 타이완엔시스 균주 및 이의 용도에 관한 것이다.
본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주 또는 그 배양액을 포함하는 조성물은 다양한 균들에 대해 폭넓은 항균 스펙트럼을 나타내고 있으며, 본 발명의 조성물은 유해세균에 의해 발생하는 다양한 세균 감염증에 적용이 가능하다.
또한, 본 발명의 조성물은 의약, 건강기능식품, 또는 사료 보존제 등의 다양한 분야에서 항균 목적으로 유용하게 이용가능하다.The present invention relates to a Lactobacillus taiwanensis strain having antibacterial and antifungal activity and uses thereof.
The composition containing the Lactobacillus taiwanensis NIBRBA00501006 strain of the present invention or a culture solution thereof exhibits a broad antimicrobial spectrum against various bacteria, and the composition of the present invention can be applied to various bacterial infections caused by harmful bacteria.
In addition, the composition of the present invention can be usefully used for antibacterial purposes in various fields such as medicine, health functional food, or feed preservative.
Description
본 발명은 유해세균에 대해 항균 활성을 갖는 락토바실러스 타이완엔시스 균주 및 이의 용도에 관한 것이다.The present invention relates to a Lactobacillus taiwanensis strain having an antibacterial activity against harmful bacteria and a use thereof.
생물체의 항상성(homeostasis)을 유지하기 위한 과정에서 중요한 역할을 담당하고 있는 물질들 중 일부가 각종 생물체 유래의 생리 활성 물질이다. 지금까지 수많은 생리 활성 물질에 대해 많은 연구가 진행되고 있으며, 그 중, 항균 및 항진균 물질에 관한 연구는 생명과학 및 의학 분야에서 매우 중요한 영역이다.Some of the substances that play an important role in the process of maintaining the homeostasis of living organisms are bioactive substances derived from various organisms. There are many studies on numerous bioactive substances so far, and among them, studies on antibacterial and antifungal substances are very important areas in the fields of life science and medicine.
모든 생명체는 생존을 위하여 항균 및 항진균 물질을 생산하는 것으로 알려져 있는데, 항균 및 항진균 물질을 생산하는 미생물에 대해서 많은 연구가 이루어지고 있으며, 항균 및 항진균 물질을 생산하는 미생물 또는 이들에게서 분리된 물질을 이용해 항균제를 개발하려는 연구들이 오래전부터 시도되고 있다.All living organisms are known to produce antibacterial and antifungal substances for survival, and a lot of research has been conducted on microorganisms that produce antibacterial and antifungal substances, and microorganisms that produce antibacterial and antifungal substances or substances separated from them are used. Studies to develop antibacterial agents have been attempted for a long time.
한편, 유산균(lactic acid bacteria)은 당을 발효시켜 유산을 생성하는 간균으로, 우리 몸을 건강하게 도와주는 유용물질을 생산하고, 면역증강, 항산화, 항균, 항콜레스테롤, 항비만, 발암 및 변이 물질의 생성을 방지하는 기능 등을 갖는 것으로 알려져 있다. On the other hand, lactic acid bacteria is a bacillus that produces lactic acid by fermenting sugar. It produces useful substances that help our body health, and improves immunity, antioxidants, antibacterials, anti-cholesterol, anti-obesity, carcinogenic and mutant substances. It is known to have a function of preventing the generation of.
유산균이 생성하는 항균성 대사산물로는 유기산(Organic acids), 과산화수소(hydrogen peroxide), 디아세틸(diacetyl), 베타-하이드록시프로피온알데하이드(b-hydroxypropionaldehyde), 박테리오신(bacteriocins) 등이 보고된 바 있다(Adams and Hall 1988; 1993; Plockova 1997). 그 중 박테리오신은 다른 항생제와 구별되는 항균활성을 갖는 천연물질로서 그람양성균과 그람음성균의 생육에 영향을 미치는 단백질성 항생물질로 알려져 있다(Abdel-Bar 1987, ten Brink 1994). 각종 병원균과 유해미생물에 대한 유산균의 항균작용에 관한 많은 연구가 국내외적으로 계속 되고 있으나(Fank 1991, Gilliland and Speck 1977, Lewus 1991, Kim 1997), 아직까지 산업적으로 유용하게 이용될 수 있을만큼 강력한 항균 활성을 갖는 유산균은 많지 않으며, 유산균의 발효산물 중 어떤 물질이 인체에 유익한 작용을 하는지 명확히 규명되어 있지 않다(Mcfarland and Elmer 1995, Sanders 1999). As antimicrobial metabolites produced by lactic acid bacteria, organic acids, hydrogen peroxide, diacetyl, beta-hydroxypropionaldehyde, and bacteriocins have been reported ( Adams and Hall 1988; 1993; Plockova 1997). Among them, bacteriocin is a natural substance with antibacterial activity that is distinct from other antibiotics, and is known as a proteinaceous antibiotic that affects the growth of Gram-positive and Gram-negative bacteria (Abdel-Bar 1987, ten Brink 1994). Although many studies on the antibacterial activity of lactic acid bacteria against various pathogens and harmful microorganisms have been conducted domestically and internationally (Fank 1991, Gilliland and Speck 1977, Lewus 1991, Kim 1997), it is still strong enough to be useful industrially. There are not many lactic acid bacteria that have antibacterial activity, and it is not clear which substances among the fermentation products of lactic acid bacteria have beneficial effects on the human body (Mcfarland and Elmer 1995, Sanders 1999).
또한, 식품에서 유산균은 발효식품의 맛과 발효산물의 특징을 결정하고, 유기산 및 박테리오신 등의 항균활성을 갖는 물질을 생성하여 식품의 저장성에 기여한다. 박테리오신은 다양한 그람 양성균에서 생산되는 항균 활성 단백질 또는 펩타이드이며, 유산균에서 유래한 박테리오신의 경우 식품산업에서 천연보존제(natural preservative)로 이용할 수 있는 응용성과 항생제를 대체할 수 있는 물질로서 관심을 끌고 있다. 클라엔하머(Klaenhammer)는 유산균이 생산하는 박테리오신을 분자구조 및 생리학적 특성에 따라 다음과 같이 분류하였다. In addition, in food, lactic acid bacteria determine the taste of fermented foods and characteristics of fermented products, and contribute to the storage of food by generating substances having antibacterial activity such as organic acids and bacteriocin. Bacteriocin is an antimicrobial active protein or peptide produced from various Gram-positive bacteria, and bacteriocin derived from lactic acid is attracting attention as a substance that can be used as a natural preservative in the food industry and as a substitute for antibiotics. Klaenhammer classified bacteriocins produced by lactic acid bacteria according to molecular structure and physiological characteristics as follows.
Class I 박테리오신(lantibiotics)은 번역후변형(post-translational modification) 결과 란티오닌(lanthionine)과 같은 특이 아미노산을 포함한다. Class II 박테리오신은 란티오닌을 함유하지 않는 박테리오신으로 분자량이 작고(<13 kDa), 작은 분자량으로 인하여 3차 구조를 형성하지 않으므로 비교적 열에 안정하고, 일반적으로 20개 정도의 소수성 아미노산으로 이루어진 막전위 헬릭스(transmembrane helix) 구조를 갖는 것을 특징으로 한다. Class III 박테리오신은 분자량이 크고(>30 kDa), 열에 불안정한 항균활성 단백질이다. 그 예로, 락토코쿠스 락티스(Lactococcus lactis)가 생산하는 니신(nisin)은 Class I 유형에 속하며 비교적 넓은 항균 스펙트럼(antimicrobial spectrum)을 가지고 대부분의 그람 양성균의 증식을 억제한다. 니신(Nisin)은 열에 안정하고 낮은 pH 조건에서도 활성을 나타내며 천연 식품보존제로 사용되고 있다. 또한 대부분의 박테리오신의 활성은 약산성에서 강하고 염기성 환경에서 불안정한 것으로 알려져 산을 생성하는 락토바실러스(Lactobacillus) 속의 배양액으로부터 박테리오신의 생산 여부를 알아보기 위해 광범위하게 적용할 수 있는 실험적 방법의 확립에 어려움이 있었다. Class I bacteriocins contain specific amino acids such as lanthionine as a result of post-translational modification. Class II bacteriocin is a bacteriocin that does not contain lanthionine and has a small molecular weight (<13 kDa) and does not form a tertiary structure due to its small molecular weight, so it is relatively stable to heat, and is generally a membrane potential helix composed of about 20 hydrophobic amino acids. It is characterized by having a (transmembrane helix) structure. Class III bacteriocin is a high molecular weight (>30 kDa), heat-labile antibacterial active protein. For example, the nisin produced by Lactococcus lactis belongs to the Class I type and has a relatively broad antimicrobial spectrum and inhibits the proliferation of most Gram-positive bacteria. Nisin is heat-stable and active even in low pH conditions, and is used as a natural food preservative. In addition, most of the bacteriocin activity is known to be strong in weak acidity and unstable in a basic environment, and it was difficult to establish an experimental method that can be widely applied to determine whether bacteriocin is produced from the culture medium of the genus Lactobacillus that produces acid. .
이러한 배경 하에서, 본 발명자들은 우수한 항균 활성을 갖는 유산균 균주를 발굴하기 위해 예의 노력한 결과, 신균주 락토바실러스 타이완엔시스 NIBRBA00501006 균주가 우수한 항균 활성을 갖는 박테리오신을 분비하는 효능이 있어, 항균제, 건강기능식품, 식품보존제, 사료첨가제 등에 유용하게 활용할 수 있음을 확인하고, 본 발명을 완성하게 되었다.Under this background, the present inventors made diligent efforts to discover lactic acid bacteria strains having excellent antibacterial activity, as a result of which the new strain Lactobacillus Taiwan Nsis NIBRBA00501006 strain has the effect of secreting bacteriocin having excellent antibacterial activity, antibacterial agents, health functional foods After confirming that it can be usefully used for food preservatives and feed additives, this invention was completed.
따라서, 본 발명의 주된 목적은 항균 활성을 갖는 락토바실러스 타이완엔시스 균주를 제공하는 데 있다.Accordingly, the main object of the present invention is to provide a Lactobacillus taiwanensis strain having antibacterial activity.
본 발명의 다른 목적은 상기 락토바실러스 타이완엔시스 균주를 이용한 항균 조성물을 제공하는데 있다. Another object of the present invention is to provide an antibacterial composition using the Lactobacillus taiwanensis strain.
본 발명의 한 양태에 따르면, 본 발명은 기탁번호 KCTC 18771P로 수탁된 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주를 제공한다.According to one aspect of the invention, the present invention provides a Lactobacillus Taiwan N-Sys (Lactobacillus taiwanensis) NIBRBA00501006 strain entrusted with Accession No. KCTC 18771P.
본 발명의 용어 "락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주"는 본 발명자들에 의해 새롭게 분리 동정된 신규한 락토바실러스 타이완엔시스 균주로서, "NIBRBA00501006 균주" 또는 "NIBRBA00501006"과 혼용하여 사용할 수 있다.Terms of the present invention, "Lactobacillus Taiwan N-Sys (Lactobacillus taiwanensis) NIBRBA00501006 strain" may be used interchangeably as the novel Lactobacillus Taiwan N-Sys strains identified separating newly by the present inventors, and "NIBRBA00501006 strain" or "NIBRBA00501006".
본 발명자들은 신규 항균제의 개발을 위해 유산균의 항균 효과에 대해 수년간 조사 분석하였고, 그 결과 락토바실러스 타이완엔시스의 강력한 항균 효과를 검증하고 본 발명을 완성하였다(도 1 내지 도 8 참조).The present inventors investigated and analyzed the antibacterial effect of lactic acid bacteria for several years for the development of a new antibacterial agent, and as a result, verified the strong antibacterial effect of Lactobacillus taiwanensis and completed the present invention (see FIGS. 1 to 8).
본 발명자들은 유전자 서열 분석을 본 발명의 균주가 갖는 유전자 서열을 종래 공지된 균주들의 유전자 서열들과 비교 분석한 결과, 본 발명의 균주가 락토바실러스 타이완엔시스에 속하는 새로운 균주임을 확인하여 락토바실러스 타이완엔시스 NIBRBA00501006으로 명명하였고, 이를 한국생명공학연구원 생물자원센터에 2019년 05월 10일자로 기탁하고, 수탁번호 KCTC 18771P를 부여받았다. The present inventors compared the gene sequence of the strain of the present invention with the gene sequences of conventionally known strains, and confirmed that the strain of the present invention is a new strain belonging to Lactobacillus taiwanensis. It was named NIBRBA00501006, and it was deposited with the Korea Research Institute of Bioscience and Biotechnology Biological Resource Center on May 10, 2019, and was given the accession number KCTC 18771P.
또한, 본 발명의 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주는 살모넬라 속 균주, 에스체리치아 속 균주, 스트렙토코커스 속 균주, 바실러스 속 균주, 및 사카로마에세스 속 균주로 구성된 군으로부터 선택되는 어느 하나 이상의 병원균에 대해 항균 활성을 갖는 것을 특징으로 하는데, 상기 살모넬라 속 균주의 예로는 살모넬라 겔린아룸(Salmonella gallinarum)이 있고, 상기 에스체리치아 속 균주의 예로는 에스체리치아 콜라이(E. coli)가 있으며, 상기 스트렙토코커스 속 균주의 예로는 스트렙토코커스 이니에(Streptococcus iniae)가 있고, 상기 바실러스 속 균주의 예로는 바실러스 세레우스(B. cereus)가 있으며, 상기 사카로마에세스 속 균주의 예로는 사카로마에세스 세레비제(S. cerevisiae)를 들 수 있으나, 이에 제한되는 것은 아니다. In addition, any one Lactobacillus Taiwan N-Sys (Lactobacillus taiwanensis) NIBRBA00501006 strain of the present invention is selected from Salmonella spp, S. Cherry teeth sp, Streptococcus sp, Bacillus sp, and the group consisting of a recess in the strain in Saccharomyces Rome It is characterized in that it has antibacterial activity against the above pathogens. Examples of the strain of the genus Salmonella include Salmonella gallinarum , and examples of the strain of the genus Escherichia include E. coli. In addition, examples of the strain of the genus Streptococcus include Streptococcus iniae , and examples of the strain of the genus Bacillus include B. cereus , and examples of the strain of the genus Saccharomyces include Saccharomyces. Rome Esces cerevisiae (S. cerevisiae) may be mentioned, but is not limited thereto.
본 발명의 다른 양태에 따르면, 본 발명은 락토바실러스 타이완엔시스(Lactobacillus taiwanensis ) NIBRBA00501006 균주(기탁번호 KCTC 18771P), 상기 균주의 배양액, 상기 배양액의 농축물 및 상기 배양액의 건조물로 구성된 군으로부터 선택된 어느 하나 이상을 유효성분으로 포함하는 발효용 스타터(starter)를 제공한다. 본 발명에서 상기 발효용 스타터란 발효에 관여하는 유산균 또는 세균 등을 포함하는 미생물, 이의 배양물, 상기 배양물의 농축물 및 상기 배양물의 건조물로 이루어진 군 중에서 선택된 어느 하나를 포함하는 제제 또는 조성물을 의미하며, 발효용 스타터는 발효식품 등의 생산시 첨가하여 발효식품에서 생장할 수 있는 미생물 또는 우점종으로 생장할 수 있는 미생물을 제공하기 위하여 사용된다. 상기 발효용 스타터를 사용하여 발효식품을 제조하는 경우, 상기 발효용 스타터에 포함된 미생물에 의하여 발효식품의 품질을 일정하게 조절하거나, 발효의 속도 또는 단계를 조절할 수 있으며, 특정한 목적을 달성한 발효식품을 제조할 수 있다. 또한, 상기 발효용 스타터에는 통상적으로 사용되는 첨가제를 더 포함할 수 있다.According to another aspect of the invention there is provided Lactobacillus Taiwan N-Sys (Lactobacillus taiwanensis) NIBRBA00501006 strain (Accession No. KCTC 18771P), the culture medium of the strain, at least one selected of the culture solution concentrate and from the group consisting of a dried product of the culture broth It provides a starter for fermentation comprising the above as an active ingredient. In the present invention, the fermentation starter refers to a preparation or composition comprising any one selected from the group consisting of a microorganism including lactic acid bacteria or bacteria involved in fermentation, a culture thereof, a concentrate of the culture, and a dried product of the culture In addition, the fermentation starter is used to provide microorganisms that can grow in fermented foods or as dominant species by adding them in the production of fermented foods. In the case of manufacturing fermented food using the fermentation starter, the quality of the fermented food can be constantly controlled by microorganisms included in the fermentation starter, or the speed or stage of fermentation can be controlled, and fermentation that achieves a specific purpose You can make food. In addition, the fermentation starter may further include commonly used additives.
본 발명의 상기 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주는 병원성 세균의 생장을 저해하고, 각종 병원성 미생물에 대한 항균 활성이 우수하며, 인체에 무해하므로, 안전한 발효식품 제조에 있어서 발효용 스타터로 유용하게 이용될 수 있다.The Lactobacillus taiwanensis of the present invention The NIBRBA00501006 strain inhibits the growth of pathogenic bacteria, has excellent antibacterial activity against various pathogenic microorganisms, and is harmless to the human body, so it can be usefully used as a fermentation starter in the manufacture of safe fermented foods.
본 발명의 다른 양태에 따르면, 본 발명은 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주(기탁번호 KCTC 18771P) 또는 상기 발효용 스타터를 이용하여 생산된 발효식품을 제공한다. 상기 발효식품이란, 유산균이나 효소 등 미생물을 하나 또는 둘 이상 첨가하고 상기 미생물의 발효 작용을 이용하여 만든 식품을 의미하며, 상세하게는 식품 기재에 발효식품용 종균을 첨가하고 숙성시켜 제조하는 식품을 의미한다. 상기 발효식품으로는 주류, 빵류, 김치, 젓갈, 된장, 간장, 치즈, 버터, 요구르트 등 비살균 개방형 발효식품 모두가 포함된다.According to another aspect of the present invention, the present invention is Lactobacillus taiwanensis It provides a fermented food produced using the NIBRBA00501006 strain (accession number KCTC 18771P) or the fermentation starter. The fermented food refers to a food prepared by adding one or two or more microorganisms such as lactic acid bacteria or enzymes, and using the fermentation action of the microorganism, and in detail, a food prepared by adding and aging fermented food seeds to a food substrate. it means. The fermented food includes all non-sterile open fermented foods such as liquor, bread, kimchi, salted fish, miso, soy sauce, cheese, butter, and yogurt.
본 발명의 다른 양태에 따르면, 본 발명은 락토바실러스 타이완엔시스(Lactobacillus taiwanensis ) NIBRBA00501006 균주(기탁번호 KCTC 18771P) 또는 상기 발효용 스타터를 원재료에 접종하는 단계를 포함하는 발효식품 제조방법을 제공한다. 상기 발효식품 제조방법은 김치, 치즈, 버터, 요구르트 등의 제조방법일 수 있으며, 상기 락토바실러스 타이완엔시스 NIBRBA00501006 균주 또는 발효용 스타터를 접종하여 발효식품의 제조에 활용할 수 있다. According to another aspect of the invention, the invention provides a fermented food manufacturing method comprising inoculation of Lactobacillus Taiwan N-Sys (Lactobacillus taiwanensis) for NIBRBA00501006 strain (Accession No. KCTC 18771P) or the fermented starter to the raw material. The fermented food manufacturing method may be a method of manufacturing kimchi, cheese, butter, yogurt, etc., and may be used in the manufacture of fermented food by inoculating the Lactobacillus Taiwan Nsis NIBRBA00501006 strain or a fermentation starter.
본 발명의 다른 양태에 따르면, 본 발명은 기탁번호 KCTC 18771P로 수탁되고, 살모넬라 속 균주, 에스체리치아 속 균주, 스트렙토코커스 속 균주, 바실러스 속 균주, 및 사카로마에세스 속 균주로 구성된 군으로부터 선택되는 어느 하나 이상의 병원균에 대해 항균 활성을 나타내며, 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주, 상기 균주의 배양액, 상기 배양액의 농축물 및 상기 배양액의 건조물로 구성된 군으로부터 선택된 어느 하나 이상을 유효성분으로 함유하는 항균용 약학적 조성물을 제공한다.According to another aspect of the present invention, the present invention is entrusted with accession number KCTC 18771P, and is selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp. It shows antimicrobial activity against any one or more pathogens, and Lactobacillus taiwanensis It provides an antimicrobial pharmaceutical composition containing as an active ingredient at least one selected from the group consisting of NIBRBA00501006 strain, a culture solution of the strain, a concentrate of the culture solution, and a dried product of the culture solution.
본 발명에서, 상기 락토바실러스 타이완엔시스 NIBRBA00501006 균주 또는 그 배양액은 그 자체로 항균 활성을 나타내는 것을 특징으로 한다. In the present invention, the Lactobacillus taiwanensis NIBRBA00501006 strain or a culture solution thereof is characterized in that it exhibits antibacterial activity.
본 발명의 상기 감염 예방 또는 치료용 약학적 조성물에서, 상기 살모넬라 속 균주의 예로는 살모넬라 겔린아룸(Salmonella gallinarum)이 있고, 상기 에스체리치아 속 균주의 예로는 에스체리치아 콜라이(E. coli)가 있으며, 상기 스트렙토코커스 속 균주의 예로는 스트렙토코커스 이니에(Streptococcus iniae)가 있고, 상기 바실러스 속 균주의 예로는 바실러스 세레우스(B. cereus)가 있으며, 상기 사카로마에세스 속 균주의 예로는 사카로마에세스 세레비제(S. cerevisiae)를 들 수 있으나, 이에 제한되는 것은 아니다. In the pharmaceutical composition for preventing or treating infections of the present invention, examples of the strain of the genus Salmonella include Salmonella gallinarum , and examples of the strain of the genus Escherichia include Escherichia coli (E. coli). An example of the strain of the genus Streptococcus is Streptococcus iniae , an example of the strain of the genus Bacillus is Bacillus cereus , and an example of the strain of the genus Saccharomyces is S. cerevisiae can be mentioned, but is not limited thereto.
한편, 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주 또는 그 배양액의 추출물은 약학적으로 허용 가능한 염의 형태로 제조될 수 있다. 구체적으로 산을 첨가함으로써 염을 형성할 수 있는데, 예를 들면 무기산(예: 염산, 히드로브롬산, 인산, 질산, 황산 등), 유기 카르복실산(예: 아세트산, 트리플루오로아세트산과 같은 할로 아세트산, 프로피온산, 말레산, 숙신산, 말산, 시트르산, 타르타르산, 살리실산), 산성 당(글루쿠론산, 갈락투론산, 글루콘산, 아스코르브산), 산성 폴리사카리드(예: 히알우론산, 콘드로이틴 술페이트, 아르기닌산), 콘드로이틴 술페이트와 같은 술폰산 당 에스테르를 포함하는 유기 술폰산(예: 메탄, 술폰산, p-톨루엔 술폰산) 등을 첨가하여 염을 형성할 수 있다.On the other hand, the Lactobacillus taiwanensis NIBRBA00501006 strain of the present invention or an extract of the culture solution may be prepared in the form of a pharmaceutically acceptable salt. Specifically, salts can be formed by adding an acid, for example, inorganic acids (eg, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), organic carboxylic acids (eg, halo acids such as acetic acid and trifluoroacetic acid). Acetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), acidic sugars (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), acidic polysaccharides (e.g. hyaluronic acid, chondroitin sulfate, arginine) Acid), an organic sulfonic acid (eg, methane, sulfonic acid, p-toluene sulfonic acid) including a sulfonic acid sugar ester such as chondroitin sulfate may be added to form a salt.
본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주 또는 그 배양액은 식용 가능한 식품에서 분리된 유산균의 일종으로 임상투여시 경구 또는 비경구로 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있다.The Lactobacillus taiwanensis NIBRBA00501006 strain or its culture medium of the present invention is a kind of lactic acid bacteria isolated from edible foods and can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical formulation.
즉, 본 발명의 신균주 NIBRBA00501006 또는 그 배양액은 실제로 경구 또는 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 리우린지, 글리세로제라틴 등이 사용될 수 있다.That is, the new strain NIBRBA00501006 of the present invention or its culture solution can be administered in various oral or parenteral formulations. In the case of formulation, diluents such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. It is formulated using excipients. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, liurinji, glycerogelatin, and the like may be used.
또한, 본 발명의 신균주 NIBRBA00501006 또는 그 배양액은 생리식염수 또는 유기용매와 같이 약제로 허용된 여러 전달체(carrier)와 혼합하여 사용될 수 있고, 안정성이나 흡수성을 증가시키기 위하여 글루코스, 수크로스 또는 덱스트란과 같은 카보하이드레이트, 아스코르브 산(ascorbic acid) 또는 글루타치온과 같은 항산화제(antioxidants), 킬레이트화제(chelating agents), 저분자 단백질 또는 다른 안정화제(stabilizers)들이 약제로 사용될 수 있다.In addition, the new strain NIBRBA00501006 of the present invention or its culture medium may be used in combination with various carriers permitted as drugs such as physiological saline or organic solvent, and glucose, sucrose or dextran and Antioxidants such as carbohydrates, ascorbic acid or glutathione, chelating agents, small molecule proteins or other stabilizers can be used as pharmaceuticals.
본 발명의 신균주 NIBRBA00501006 또는 그 배양액의 유효용량은 0.01㎎/㎏ 내지 10㎎/㎏이고, 바람직하게는 0.1㎎/㎏ 내지 1㎎/㎏ 이며, 하루 1회 내지 3회 투여될 수 있다.The effective dose of the new strain NIBRBA00501006 or its culture medium of the present invention is 0.01 mg/kg to 10 mg/kg, preferably 0.1 mg/kg to 1 mg/kg, and may be administered once to three times a day.
본 발명의 약학적 조성물에서 또는 그 배양액은 총 유효량은 볼루스(bolus) 형태 혹은 상대적으로 짧은 기간 동안 주입(infusion) 등에 의해 단일 투여량(single does)으로 환자에게 투여될 수 있으며, 다중 투여량(multiple does)이 장기간 투여되는 분할 치료 방법(fractionated treatment protocol)에 의해 투여될 수 있다. 상기 농도는 약의 투여 경로 및 치료 횟수뿐만 아니라 환자의 나이 및 건강상태 등 다양한 요인들을 고려하여 환자의 유효 투여량이 결정되는 것이므로 이러한 점을 고려할 때, 이 분야의 통상적인 지식을 가진 자라면 본 발명의 신균주 NIBRBA00501006 또는 그 배양액의 약학적 조성물로서의 특정한 용도에 따른 적절한 유효 투여량을 결정할 수 있을 것이다.In the pharmaceutical composition of the present invention or its culture medium, the total effective amount may be administered to a patient in a single dose by infusion or the like in a bolus form or for a relatively short period of time, and multiple doses (multiple does) can be administered by a fractionated treatment protocol that is administered over a long period of time. Since the concentration is determined by taking into account various factors such as the patient's age and health condition, as well as the route of administration and the number of treatments of the drug, the effective dosage of the patient is determined. It will be possible to determine an appropriate effective dose according to the specific use of the new strain of NIBRBA00501006 or its culture as a pharmaceutical composition.
본 발명의 다른 양태에 따르면, 본 발명은 기탁번호 KCTC 18771P로 수탁되고, 살모넬라 속 균주, 에스체리치아 속 균주, 스트렙토코커스 속 균주, 바실러스 속 균주, 및 사카로마에세스 속 균주로 구성된 군으로부터 선택되는 어느 하나 이상의 병원균에 대해 항균 활성을 나타내며, 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주, 상기 균주의 배양액, 상기 배양액의 농축물 및 상기 배양액의 건조물로 구성된 군으로부터 선택된 어느 하나 이상을 유효성분으로 함유하는 항균용 건강기능식품 조성물을 제공한다.According to another aspect of the present invention, the present invention is entrusted with accession number KCTC 18771P, and is selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp. It shows antimicrobial activity against any one or more pathogens, and Lactobacillus taiwanensis It provides an antimicrobial health functional food composition containing as an active ingredient any one or more selected from the group consisting of NIBRBA00501006 strain, a culture solution of the strain, a concentrate of the culture solution, and a dried product of the culture solution.
본 발명의 항균용 건강기능식품 조성물에서, 상기 살모넬라 속 균주의 예로는 살모넬라 겔린아룸(Salmonella gallinarum)이 있고, 상기 에스체리치아 속 균주의 예로는 에스체리치아 콜라이(E. coli)가 있으며, 상기 스트렙토코커스 속 균주의 예로는 스트렙토코커스 이니에(Streptococcus iniae)가 있고, 상기 바실러스 속 균주의 예로는 바실러스 세레우스(B. cereus)가 있으며, 상기 사카로마에세스 속 균주의 예로는 사카로마에세스 세레비제(S. cerevisiae)를 들 수 있으나, 이에 제한되는 것은 아니다. In the antimicrobial health functional food composition of the present invention, examples of the Salmonella genus strain include Salmonella gallinarum , and examples of the Escherichia genus strain include Escherichia coli (E. coli), and An example of the strain of the genus Streptococcus is Streptococcus iniae , an example of the strain of the genus Bacillus is Bacillus cereus , and an example of the strain of the genus Saccharomyces is Saccharomae Ses cerevisiae (S. cerevisiae) can be mentioned, but is not limited thereto.
본 발명의 건강기능식품은 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나 사카린, 아스파탐과 같은 합성 감미제 등을 사용할 수 있다.The health functional food of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients. The natural carbohydrates described above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame can be used.
상기 천연 탄수화물의 비율은 본 발명의 건강기능식품 100 중량부 당 0.01 ~ 0.04 중량부, 구체적으로는 약 0.02 ~ 0.03 중량부 범위에서 선택할 수 있다.The ratio of the natural carbohydrate may be selected from 0.01 to 0.04 parts by weight per 100 parts by weight of the health functional food of the present invention, specifically about 0.02 to 0.03 parts by weight.
상기 외에 본 발명의 건강기능식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 건강식품 100 중량부 당 0.01 ~ 0.1 중량부의 범위에서 선택될 수 있다.In addition to the above, the health functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, Carbonating agents used in carbonated beverages may be contained. These components may be used independently or in combination. The ratio of these additives is not very important, but may be selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
본 발명의 다른 양태에 따르면, 본 발명은 기탁번호 KCTC 18771P로 수탁되고, 살모넬라 속 균주, 에스체리치아 속 균주, 스트렙토코커스 속 균주, 바실러스 속 균주, 및 사카로마에세스 속 균주로 구성된 군으로부터 선택되는 어느 하나 이상의 병원균에 대해 항균 활성을 나타내며, 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주, 상기 균주의 배양액, 상기 배양액의 농축물 및 상기 배양액의 건조물로 구성된 군으로부터 선택된 어느 하나 이상을 유효성분으로 함유하는 항균용 식품 보존제 조성물을 제공한다.According to another aspect of the present invention, the present invention is entrusted with accession number KCTC 18771P, and is selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp. It shows antibacterial activity against any one or more pathogens, and any one or more selected from the group consisting of the Lactobacillus taiwanensis NIBRBA00501006 strain, the culture solution of the strain, the concentrate of the culture solution, and the dried product of the culture solution as an active ingredient It provides an antibacterial food preservative composition containing.
본 발명에서 사용되는 용어 "보존"은 미생물의 작용에 의해 식품이 부패하는 것을 막는 것을 의미하며, 항생, 항균을 총칭하는 의미로 사용된다. 또한, 용어 "보존제"는 식품을 보존하기 위한 목적으로 방부하기 위해서 첨가되는 약제를 의미한다. 따라서 인체에 해가 없어야 하며, 또 그 첨가로 인해 식품의 품질을 손상시키지 않아야 한다. The term "preservation" as used in the present invention means preventing food from spoiling due to the action of microorganisms, and is used as a generic term for antibiotics and antibacterials. In addition, the term "preservative" refers to a drug added to preservative for the purpose of preserving food. Therefore, there should be no harm to the human body, and the addition should not impair the quality of food.
본 발명의 상기 항균용 식품 보존제 조성물에서, 상기 살모넬라 속 균주의 예로는 살모넬라 겔린아룸(Salmonella gallinarum)이 있고, 상기 에스체리치아 속 균주의 예로는 에스체리치아 콜라이(E. coli)가 있으며, 상기 스트렙토코커스 속 균주의 예로는 스트렙토코커스 이니에(Streptococcus iniae)가 있고, 상기 바실러스 속 균주의 예로는 바실러스 세레우스(B. cereus)가 있으며, 상기 사카로마에세스 속 균주의 예로는 사카로마에세스 세레비제(S. cerevisiae)를 들 수 있으나, 이에 제한되는 것은 아니다. In the antibacterial food preservative composition of the present invention, examples of the Salmonella genus strain include Salmonella gallinarum , and examples of the Escherichia genus strain include Escherichia coli (E. coli), and An example of the strain of the genus Streptococcus is Streptococcus iniae , an example of the strain of the genus Bacillus is Bacillus cereus , and an example of the strain of the genus Saccharomyces is Saccharomae Ses cerevisiae (S. cerevisiae) can be mentioned, but is not limited thereto.
본 발명의 다른 양태에 따르면, 본 발명은 기탁번호 KCTC 18771P로 수탁되고, 살모넬라 속 균주, 에스체리치아 속 균주, 스트렙토코커스 속 균주, 바실러스 속 균주, 및 사카로마에세스 속 균주로 구성된 군으로부터 선택되는 어느 하나 이상의 병원균에 대해 항균 활성을 나타내며, 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주, 상기 균주의 배양액, 상기 배양액의 농축물 및 상기 배양액의 건조물로 구성된 군으로부터 선택된 어느 하나 이상을 유효성분으로 함유하는 항균용 사료첨가제 조성물을 제공한다.According to another aspect of the present invention, the present invention is entrusted with accession number KCTC 18771P, and is selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp. It shows antibacterial activity against any one or more pathogens, and any one or more selected from the group consisting of the Lactobacillus taiwanensis NIBRBA00501006 strain, the culture solution of the strain, the concentrate of the culture solution, and the dried product of the culture solution as an active ingredient It provides an antibacterial feed additive composition containing.
본 발명의 항균용 사료첨가제 조성물에서, 상기 살모넬라 속 균주의 예로는 살모넬라 겔린아룸(Salmonella gallinarum)이 있고, 상기 에스체리치아 속 균주의 예로는 에스체리치아 콜라이(E. coli)가 있으며, 상기 스트렙토코커스 속 균주의 예로는 스트렙토코커스 이니에(Streptococcus iniae)가 있고, 상기 바실러스 속 균주의 예로는 바실러스 세레우스(B. cereus)가 있으며, 상기 사카로마에세스 속 균주의 예로는 사카로마에세스 세레비제(S. cerevisiae)를 들 수 있으나, 이에 제한되는 것은 아니다. In the antibacterial feed additive composition of the present invention, examples of the Salmonella genus strain include Salmonella gallinarum , and examples of the Escherichia genus strain include Escherichia coli (E. coli). An example of the strain of the genus Streptococcus is Streptococcus iniae , an example of the strain of the genus Bacillus is Bacillus cereus , and an example of the strain of the genus Saccharomyces is Saccharomyces ces. Cerevisiae (S. cerevisiae) may be mentioned, but is not limited thereto.
특히, 본 발명의 사료첨가제는 축산 현장에서 직접 채취한 고병원성 살모넬라 균주에 대해 강력한 항균 활성을 가지므로, 가금류, 가축 등에게 꾸준히 섭취하게 함으로써 세균성 질환을 예방할 수 있고, 이미 발생한 세균성 질환을 개선시킬 수 있다. 사료는 영양가, 주성분, 유통, 수분 함량 배합상태 및 가공형태 등에 따라 여러 가지로 분류할 수 있으며, 사료는 조사료, 농후사료, 보충사료, 단백질사료, 녹말사료, 지방질사료 또는 섬유질사료가 사용가능하다.In particular, the feed additive of the present invention has a strong antibacterial activity against highly pathogenic Salmonella strains collected directly from livestock farming sites, so it is possible to prevent bacterial diseases by steadily ingesting poultry, livestock, etc., and to improve bacterial diseases that have already occurred. have. Feed can be classified into several categories according to nutritional value, main ingredient, distribution, water content, blending status, and processing type. Forage, roughage, thick feed, supplemental feed, protein feed, starch feed, fat feed or fiber feed can be used. .
상기 사료첨가제는 추가적으로 허용되는 담체를 함유할 수 있으며, 예를 들어, 상기 사료첨가제를 그대로 또는 공지의 담체, 안정제 등을 가할 수 있다. 또한, 필요에 따라 비타민, 아미노산류, 미네랄 등의 각종 양분, 항산화제, 항생물질, 항균제 및 기타의 첨가제 등을 가할 수도 있으며, 그 형상으로서는 분체, 과립, 펠릿, 현탁액 등의 적당한 상태일 수 있다. 본 발명의 사료첨가제는 단독으로 또는 사료에 혼합하여 공급할 수 있다.The feed additive may additionally contain an acceptable carrier, for example, the feed additive may be used as it is, or a known carrier or stabilizer may be added. In addition, if necessary, various nutrients such as vitamins, amino acids, minerals, antioxidants, antibiotics, antibacterial agents, and other additives may be added, and the shape may be powder, granules, pellets, suspensions, etc. . The feed additive of the present invention can be supplied alone or mixed with feed.
본 발명의 또 다른 양태에 따르면, 본 발명은 기탁번호 KCTC 18771P로 수탁되고, 락토바실러스 타이완엔시스(Lactobacillus taiwanensis ) NIBRBA00501006 균주 또는 그 배양액을 함유하는 조성물을 치료를 필요로 하는 개체에 투여하여 병원성 세균을 사멸시키는 단계를 포함하는, 인간을 제외한 동물의 세균성 감염 질환을 치료하는 방법을 제공한다.According to another aspect of the invention there is provided a pathogenic bacteria by administration to a subject in need of such treatment a composition containing a deposit number KCTC is entrusted to 18771P, Lactobacillus Taiwan N-Sys (Lactobacillus taiwanensis) NIBRBA00501006 strain or its culture broth It provides a method of treating a bacterial infection disease in a non-human animal comprising the step of killing.
본 발명에 따른 상기 치료방법은 비록 인간을 제외한 동물을 치료하는 방법이나, 인간에 있어 이러한 치료방법이 효과가 없음을 의미하는 것은 아니다. 또한, 인간의 경우 있어서 본 발명에 따른 치료용 조성물의 투여로 증상이 호전될 수 있는 세균 또는 진균 감염에 의한 질환을 갖는 것을 고려할 때, 인간의 치료에도 충분히 사용될 수 있다.Although the treatment method according to the present invention is a method of treating animals other than humans, it does not mean that such treatment methods are not effective in humans. In addition, in the case of humans, considering having a disease caused by a bacterial or fungal infection in which symptoms can be improved by administration of the therapeutic composition according to the present invention, it can be sufficiently used for human treatment.
본 발명에서 용어 "인간을 제외한 동물"은 본 발명에 따른 치료용 조성물의 투여로 증상이 호전될 수 있는 세균 또는 진균의 감염 때문에 유발되는 질환을 갖는 인간만을 제외한 소, 말, 양, 돼지, 닭, 염소, 낙타, 영양, 개 등의 동물을 의미한다. 본 발명에 따른 치료용 조성물을 인간을 제외한 동물에게 투여함으로써, 세균 및 진균 감염에 의한 질환을 효과적으로 예방 및 치료할 수 있다.In the present invention, the term "animals other than humans" refers to cattle, horses, sheep, pigs, chickens, except for humans with diseases caused by infection of bacteria or fungi that can improve symptoms by administration of the therapeutic composition according to the present invention. , Goat, camel, antelope, dog and other animals. By administering the therapeutic composition according to the present invention to animals other than humans, diseases caused by bacterial and fungal infections can be effectively prevented and treated.
본 발명에서 용어 "투여"는 어떠한 적절한 방법으로 동물에게 소정의 물질을 도입하는 것을 의미하며, 본 발명에 따른 치료용 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명에 따른 치료용 조성물은 유효성분이 표적 세포로 이동할 수 있는 임의의 장치를 사용하여 투여될 수 있다.In the present invention, the term "administration" means introducing a predetermined substance to an animal by any suitable method, and the route of administration of the therapeutic composition according to the present invention is oral or through any general route as long as it can reach the target tissue. It can be administered parenterally. In addition, the therapeutic composition according to the present invention may be administered using any device capable of moving the active ingredient to target cells.
본 발명에 따른 치료용 조성물의 바람직한 투여량은 치료 대상 동물의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 약학적 조성물은 0.01 내지 10㎎/㎏이고, 바람직하게는 0.1㎎/㎏ 내지 1㎎/㎏이며, 하루 1회 내지 3회 투여할 수 있다.A preferred dosage of the therapeutic composition according to the present invention varies depending on the condition and weight of the animal to be treated, the degree of disease, the drug form, the route of administration and the duration, but may be appropriately selected by those skilled in the art. However, for a desirable effect, the pharmaceutical composition of the present invention is 0.01 to 10 mg/kg, preferably 0.1 mg/kg to 1 mg/kg, and may be administered once to three times a day.
본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:
(ⅰ) 본 발명은 식품에서 유래한 락토바실러스 타이완엔시스 NIBRBA00501006 균주 또는 그 배양액을 유효성분으로 포함하는 항균 조성물을 제공한다.(I) The present invention provides an antimicrobial composition comprising a food-derived Lactobacillus Taiwan Nsis NIBRBA00501006 strain or a culture solution thereof as an active ingredient.
(ⅱ) 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주 또는 그 배양액을 포함하는 조성물은 다양한 균들에 대해 폭넓은 항균 스펙트럼을 나타내고 있으며, 본 발명의 조성물은 유해세균에 의해 발생하는 다양한 세균 감염증에 적용이 가능하다. (Ii) The composition containing the Lactobacillus taiwanensis NIBRBA00501006 strain or its culture medium of the present invention exhibits a broad antibacterial spectrum against various bacteria, and the composition of the present invention can be applied to various bacterial infections caused by harmful bacteria. Do.
(ⅲ) 또한, 본 발명의 조성물은 의약, 건강기능식품, 또는 사료 보존제 등의 다양한 분야에서 항균 목적으로 유용하게 이용가능하다.(Iii) In addition, the composition of the present invention can be usefully used for antibacterial purposes in various fields such as medicine, health functional food, or feed preservative.
도 1은 살모넬라 겔린아룸(그람음성, Salmonella gallinarum), 에스체리치아 콜라이(그람음성, E. coli), 스트렙토코커스 이니에(그람양성, Streptococcus iniae), 바실러스 세레우스(그람양성, B. cereus), 및 사카로마에세스 세레비제(효모, S. cerevisiae) 균주에 대한 본 발명의 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주의 항균 활성을 측정한 그래프이다.
도 2는 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주의 배양 상등액이 병원성 세균의 균체량 변화에 따라 나타내는 항균 활성을 측정한 그래프이다.
도 3은 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주 배양 상등액에 Proteinase K를 처리한 후 항균 활성을 측정한 그래프이다.
도 4는 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주 배양 상등액에 EDTA를 처리한 후 항균 활성을 측정한 그래프이다.
도 5는 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주 배양 상등액의 50% 메탄올 분획물이 갖는 항균 활성을 측정한 그래프이다.
도 6은 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주의 메탄올 분획물/chloroform 물층에 대한 Sep-Pak R18 column 정제물의 항균 활성을 측정한 그래프이다.
도 7은 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주의 메탄올 분획물/Ethyl acetate 물층에 대한 Sep-Pak R18 column 정제물의 항균 활성을 측정한 그래프이다.
도 8은 본 발명의 락토바실러스 타이완엔시스 NIBRBA00501006 균주의 Sep-Pak R18 column 정제물(FT)을 병원성 세균인 살모넬라 겔린아룸(Salmonella gallinarum)에 처리한 후 관찰한 SEM 사진이다. 1 shows Salmonella gelin arum (Gram negative, Salmonella gallinarum ), Escherichia coli (Gram negative, E. coli), Streptococcus inie (Gram positive, Streptococcus iniae ), Bacillus cereus (Gram positive, B. cereus) ), and Saccharomyces cerevisiae (yeast, S. cerevisiae) strain of the present invention Lactobacillus taiwanensis ( Lactobacillus taiwanensis) NIBRBA00501006 It is a graph measuring the antibacterial activity of the strain.
Figure 2 is a graph measuring the antimicrobial activity of the culture supernatant of the Lactobacillus taiwanensis NIBRBA00501006 strain of the present invention according to changes in the amount of pathogenic bacteria.
Figure 3 is a graph measuring the antimicrobial activity after the treatment of Proteinase K in the culture supernatant of Lactobacillus taiwanensis NIBRBA00501006 strain of the present invention.
Figure 4 is a graph measuring the antibacterial activity after treatment with EDTA in the culture supernatant of Lactobacillus taiwanensis NIBRBA00501006 strain of the present invention.
Figure 5 is a graph measuring the antimicrobial activity of the 50% methanol fraction of the culture supernatant of Lactobacillus taiwanensis NIBRBA00501006 strain culture of the present invention.
6 is a graph measuring the antimicrobial activity of the purified Sep-Pak R18 column against the methanol fraction / chloroform water layer of the Lactobacillus taiwanensis NIBRBA00501006 strain of the present invention.
7 is a graph measuring the antibacterial activity of the purified Sep-Pak R18 column against the methanol fraction/Ethyl acetate water layer of the Lactobacillus Taiwan Nsis NIBRBA00501006 strain of the present invention.
Figure 8 is a SEM photograph observed after treating the Sep-Pak R18 column purified product (FT) of the Lactobacillus taiwanensis NIBRBA00501006 strain of the present invention in Salmonella gallinarum, a pathogenic bacterium.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail through examples. Since these examples are for illustrative purposes only, the scope of the present invention is not to be construed as being limited by these examples.
실시예 1. 균주 확보 및 L. taiwanesis 배양 상등액 제조Example 1. Securing strain and preparing L. taiwanesis culture supernatant
1-1. 균주1-1. Strain
실험에 사용된 균주는 국립생물자원관(National Institute of Biological Resoures; NIBR)이 국내에서 분리하여 보관 중인 락토바실러스 타이완엔시스(L. taiwanensis) NIBRBA00501006 균주를 분양받아 본 연구에 사용하였다. The strain used in the experiment was L. taiwanensis (L. taiwanensis) NIBRBA00501006 strain, which was isolated and stored in Korea by the National Institute of Biological Resoures (NIBR), and was used in this study.
병원성 미생물인 살모넬라 겔린아룸(Salmonella gallinarum), 병원성 E. coli, 및 스트렙토코커스 이니에(Streptococcus iniae)는 충북대학교(Chonbuk National University, Iksan, Korea) 허진 교수 연구실 및 경북대학교(Gyeongsang National University) 정태성 교수 연구실에서 분양받아 사용하였다. 바실러스 세레우스(B. cereus)(ATCC 1178) 및 사카로마에세스 세레비제(S. cerevisiae)(KCTC 27134) 균주는 한국생명공학연구원 생물자원센터(KCTC, Korean Collection for Type Cultures)에서 분양받아 사용하였다. The pathogenic microorganisms Salmonella gallinarum , pathogenic E. coli, and Streptococcus iniae are the laboratory of Prof. Jin Heo of Chungbuk National University (Iksan, Korea) and Tae- Sung Jeong of Gyeongsang National University. It was used after being sold in the professor's lab. Bacillus cereus (ATCC 1178) and S. cerevisiae (KCTC 27134) strains are sold and used at the Korea Research Institute of Bioscience and Biotechnology (KCTC, Korean Collection for Type Cultures) strains. I did.
살모넬라 겔린아룸, 병원성 E. coli, 스트렙토코커스 이니에, 및 바실러스 세레우스는 37℃에서 배양한 반면, 사카로마에세스 세레비제는 30℃에서 배양하였다. Salmonella gelin arum, pathogenic E. coli, Streptococcus inie, and Bacillus cereus were cultured at 37°C, whereas Saccharomyces cerevise was cultured at 30°C.
1-2. L. 1-2. L. taiwanesistaiwanesis 배양 상등액 제조 Preparation of culture supernatant
싱글 콜로니 유도를 통하여 락토바실러스 타이완엔시스(L. taiwanensis) NIBRBA00501006 단일 균주를 확보하였다. 확보된 단일 균주부터 5mL MRS 액체 배지에 1/100로 접종하여 37℃, 24~48시간 배양하였다. 배양 후, 1 mL씩 분취하여 13,500 RPM에서 원심 분리하였다. 원심 분리 후 상등액을 채취하여 0.2um syringe filler로 여과한 후, -20℃에 보관하면서 실험에 사용하였다.Lactobacillus taiwanensis (L. taiwanensis) NIBRBA00501006 single strain was obtained by inducing a single colony. The obtained single strain was inoculated in 5mL MRS liquid medium at 1/100 and cultured at 37°C for 24 to 48 hours. After incubation, 1 mL was aliquoted and centrifuged at 13,500 RPM. After centrifugation, the supernatant was collected, filtered with a 0.2um syringe filler, and stored at -20℃ for use in experiments.
실시예 2. L. taiwanesis 균주의 minimal inhibitory concentration(MIC) 분석Example 2. Analysis of minimal inhibitory concentration (MIC) of L. taiwanesis strain
선별된 균주들의 MIC 측정을 위하여 그람 음성균인 살모넬라 겔린아룸(Salmonella gallinarum)(SG), 병원성 E. coli JOL418(EC)을 사용하였다. 이들 균주는 모두 축산 질병원인균이다. 특히 살모넬라 겔린아룸은 닭에 있어 티푸스 원인균으로 알려져 있다. 또한, 그람 양성균으로 사람에 식중독을 일으키는 원인균인 바실러스 세레우스(B. cereus)(BC)와 어류 질병균인 스트렙토코커스 이니에(Streptococcus iniae)(SI)를 사용하였다. 또한, 곰팡이류에 대한 항균력을 알아보기 위해 질병원인균은 아니지만, 잘 알려져 있는 사카로마에세스 세레비제를 사용하였다. For the MIC measurement of the selected strains, Gram-negative bacteria Salmonella gallinarum (SG) and pathogenic E. coli JOL418 (EC) were used. All of these strains are causes of livestock disease. In particular, Salmonella gelin arum is known as the causative agent of typhus in chickens. In addition, as Gram-positive bacteria, Bacillus cereus (BC), which is the causative agent of food poisoning in humans, and Streptococcus iniae (SI), which are fish disease bacteria, were used. In addition, in order to find out the antibacterial activity against fungi, Saccharomyces cerevise, which is not a disease-causing bacterium, was used.
상기 5종의 병원균을 DISC 또는 마이크로타이터 플레이트(microtiter plate) 방법으로 최소 억제 농도(minimal inhibitory concentration, MIC) 분석을 수행하였다. 항균 분석을 위해 overnight(O/N)으로 전배양된 균주는 1×106 CFU/ml로 맞추어 실험에 사용되었다. 반응액을 마이크로타이터 플레이트에 첨가하거나 디스크(disc)에 점적한 후, 37℃에서 O/N 배양하면서 반응 성상을 관찰하였다. The five pathogens were analyzed for minimal inhibitory concentration (MIC) by DISC or microtiter plate method. For the antibacterial analysis, the strain pre-cultured overnight (O/N) was adjusted to 1×10 6 CFU/ml and used in the experiment. After adding the reaction solution to a microtiter plate or dropping it on a disc, the reaction properties were observed while incubating O/N at 37°C.
그 결과, 그람 음성균인 살모넬라 겔린아룸과 병원성 E. coli에 대해 각각 12.2ul와 12.0ul의 MIC 값이 관찰되어 높은 항균 활성을 보이는 것으로 나타났다. 이러한 항균 활성 값은 기존에 연구된 강력한 항균 활성을 갖는 균주인 락토바실러스 플란타넘(L. plantarum) 균주의 MIC 값 13.4ul 보다 우수한 항균 활성이다(도 1 참조). As a result, MIC values of 12.2ul and 12.0ul were observed for gram-negative bacteria, Salmonella gelin arum and pathogenic E. coli, respectively, showing high antibacterial activity. This antimicrobial activity value is an antimicrobial activity superior to the MIC value of 13.4ul of the L. plantarum strain, which is a strain having strong antibacterial activity previously studied (see FIG. 1).
또한, 그람 양성균인 스트렙토코커스 이니에(Streptococcus iniae)와 바실러스 세레우스(B. cereus)에 대해서도 항균 활성을 보였지만, Gram(-)에 비교하여 5.3~5.7배 낮은 활성을 나타내었다. 다른 한편으로 사카로마에세스 세레비제에 대해서도 활성을 나타내었지만, 세균류에 비교하여 2.4[Gram(+)] 내지 13.6[Gram (-)]배 낮은 활성을 보였다. In addition, gram-positive bacteria Streptococcus iniae ( Streptococcus iniae ) and Bacillus cereus (B. cereus ) also showed antibacterial activity, but showed 5.3 to 5.7 times lower activity compared to Gram (-). On the other hand, it also showed activity against Saccharomyces cerevise, but showed 2.4[Gram(+)] to 13.6[Gram(-)] times lower activity than that of bacteria.
상기와 같은 결과를 통해 본 발명의 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주의 배양 상등액은 광범위한 미생물에 대한 항균 활성을 나타내고, 특히 그람 음성균에 대한 높은 항균 활성을 나타내는 것을 확인할 수 있었다. With the results shown in the culture supernatant of Lactobacillus Taiwan N-Sys (Lactobacillus taiwanensis) NIBRBA00501006 strain of the present invention exhibit antibacterial activity against a wide range of microorganisms, it was confirmed that in particular exhibits a high antibacterial activity against gram-negative bacteria.
실시예 3. 대상 균주량에 따른 항균 활성 분석Example 3. Analysis of antibacterial activity according to the amount of target strain
이전 연구를 통해 대부분 미생물이 생산하는 항균성 펩타이드(AMPs)들은 대상 균주의 농도에 반비례하는 특성을 보였다. 따라서 본 발명의 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주의 배양 상등액에 포함된 항균물질이 동일한 성상을 갖는지를 확인하기 위해 그람 음성 균주 중 살모넬라 겔린아룸(Salmonella gallinarum)과 그람양성 균주 중 바실러스 세레우스(B. cereus) 균주를 대상으로 하여 104 ~ 108 CFU/ml의 농도로 조절하여 항균 활성의 특성을 분석해 보았다. In previous studies, most of the antimicrobial peptides (AMPs) produced by microorganisms showed inversely proportional to the concentration of the target strain. Thus Bacillus of the present invention Lactobacillus bacteria Taiwan N-Sys (Lactobacillus taiwanensis) the antibacterial substances contained in the culture supernatant of NIBRBA00501006 strain is gram to verify has the same properties voice strain of Salmonella gel rinah room (Salmonella gallinarum) and gram-positive strains celebrity Mouse (B. cereus ) strain was controlled to a concentration of 10 4 ~ 10 8 CFU / ml to analyze the characteristics of antibacterial activity.
그람 음성 균주 중 살모넬라 겔린아룸(Salmonella gallinarum)과 그람양성 균주 중 바실러스 세레우스(B. cereus) 균주 량에 따른 항균 활성 분석을 위해 상등액은 바실러스 세레우스(B. cereus)와 바실러스 세레우스(B. cereus) 106 CFU/ml에서 결정된 MIC 농도를 사용하였다.Gram supernatant for antimicrobial activity assays according to Bacillus cereus (B. cereus) Salmonella strain amount of gel rinah room voice strain (Salmonella gallinarum) and Gram-positive strain is Bacillus cereus (B. cereus) and Bacillus cereus (B cereus ) The MIC concentration determined at 10 6 CFU/ml was used.
균주량에 따른 분석을 위해 살모넬라 겔린아룸(Salmonella gallinarum)과 바실러스 세레우스(B. cereus) 균주는 108, 107, 106, 105, 104, 및 103 CFU/ml의 농도로 희석하여 사용하였다. 반응액을 마이크로타이터 플레이트에 첨가하거나 디스크(disc)에 점적한 후 37℃에서 O/N 배양하면서 반응 성상을 관찰하였다.For analysis according to the amount of strain, Salmonella gallinarum and Bacillus cereus strains were at concentrations of 10 8 , 10 7 , 10 6 , 10 5 , 10 4 , and 10 3 CFU/ml. It was diluted and used. After adding the reaction solution to a microtiter plate or dropping it on a disc, the reaction properties were observed while incubating O/N at 37°C.
그 결과, 도 2에 나타난 바와 같이 본 발명의 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주 배양 상등액은 살모넬라 겔린아룸(Salmonella gallinarum)과 바실러스 세레우스(B. cereus) 균주의 농도에 반비례하여 활성이 나타났고, 이를 통해 항균성 펩타이드(AMPs)를 포함하는 것으로 추정되었다. As a result, as shown in Figure 2, the Lactobacillus taiwanensis ( Lactobacillus taiwanensis) NIBRBA00501006 strain culture supernatant of the present invention is active in inverse proportion to the concentration of Salmonella gallinarum and Bacillus cereus (B. cereus ) strains. Appeared, and it was estimated to contain antimicrobial peptides (AMPs).
실시예 4. Proteinase K 처리에 따른 활성 평가Example 4. Evaluation of activity according to Proteinase K treatment
락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주 배양 상등액에 포함된 항균물질이 AMPs 물질인지를 확인하기 위해 proteinase K를 처리하였다.The antimicrobial materials contained in the N-Sys Taiwan Lactobacillus (Lactobacillus taiwanensis) NIBRBA00501006 strain culture supernatant was treated with proteinase K to determine whether AMPs material.
실험은 그람 음성균인 살모넬라 겔린아룸(Salmonella gallinarum)을 이용하여 디스크(disc) 또는 마이크로타이터 플레이트 방법으로 분석을 수행하였다. 상등액은 MIC 결과값인 12.19ul를 사용하였고, 균주는 1×106 CFU/ml 농도로 사용하였다. Proteinase K는 0.2mg/ml의 농도로 사용하였으며, 배양 온도는 37℃로 설정하여 평가하였다.The experiment was performed using a Gram-negative bacteria, Salmonella gallinarum , by a disc or microtiter plate method. The supernatant was used as the MIC result of 12.19ul, and the strain was used at a concentration of 1×10 6 CFU/ml. Proteinase K was used at a concentration of 0.2mg/ml, and the culture temperature was set to 37°C for evaluation.
그 결과, 도 3에 나타난 바와 같이 proteinase K를 처리했을 때 대부분의 항균 활성이 상실되는 것을 확인할 수 있었다. 따라서 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주 배양 상등액의 항균물질은 대부분 또는 모두가 AMPs 물질에 의해 활성을 보이는 것으로 추정되었다.As a result, it was confirmed that most of the antibacterial activity was lost when proteinase K was treated as shown in FIG. 3. Therefore Lactobacillus Taiwan antibacterial substance of N-Sys (Lactobacillus taiwanensis) NIBRBA00501006 strain culture supernatant was estimated to exhibit most or all of the active substance by the AMPs.
실시예 5. EDTA와 동시 처리에 따른 활성 평가Example 5. Evaluation of activity according to simultaneous treatment with EDTA
EDTA는 킬레이팅 에이전트(chelating agent)로 2가 양이온에 의존하는 효소 활성을 저해하는 기능이 있다. 많은 프로테아제(Protease)는 활성을 위해 2가 양이온을 요구하므로 용액 중에 2가 양이온의 가용성 함량을 감소시키면, 효소의 활성이 저감되는 효과가 있다. 따라서 처리되는 상등액의 프로테아제에 대한 안정성을 개선하는 효과를 유도할 수 있는 것으로 판단되었다. EDTA is a chelating agent and has a function of inhibiting enzyme activity dependent on divalent cations. Since many proteases require divalent cations for activity, reducing the soluble content of divalent cations in the solution has the effect of reducing the activity of the enzyme. Therefore, it was determined that the effect of improving the stability of the supernatant to be treated with respect to the protease can be induced.
측정을 위하여 그람 음성균인 살모넬라 겔린아룸(Salmonella gallinarum)을 이용하여 마이크로타이터 플레이트에 첨가하거나 디스크(disc)에 점적하는 방법으로 분석을 수행하였다. 상등액은 MIC 값 농도인 12.19ul를 사용하였고, 균주는 1×108 CFU/ml 농도로 사용하였다. EDTA는 0, 1, 5, 10, 15, 20, 25, 및 30mM 농도로 처리하였으며, 배양 온도는 37℃로 설정하여 평가하였다.For the measurement, analysis was performed by adding to a microtiter plate or dropping onto a disc using Salmonella gallinarum , which is a gram-negative bacterium. The supernatant was used as the MIC value of 12.19ul, and the strain was used as a concentration of 1×10 8 CFU/ml. EDTA was treated at concentrations of 0, 1, 5, 10, 15, 20, 25, and 30 mM, and the culture temperature was set to 37°C for evaluation.
그 결과, 도 4에 나타난 바와 같이 EDTA를 처리하지 않은 대조군과 비교하여 항균 활성이 상승하는 경향성을 보였고, EDTA의 농도에 비례하여 항균 활성이 증가하는 양상이 관찰되었다. 단, 16mM EDTA 이상의 농도에서는 포화되어 더 이상의 활성 증진이 나타나지 않았다. 이러한 결과를 통해 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주 배양 상등액의 항균물질은 AMPs 물질에 의해 활성을 보이는 것을 확인할 수 있었다.As a result, as shown in FIG. 4, the antimicrobial activity tended to increase compared to the control group not treated with EDTA, and the antimicrobial activity was observed to increase in proportion to the concentration of EDTA. However, at a concentration of 16 mM EDTA or higher, it was saturated and no further enhancement of activity was observed. Antimicrobial agents of N-Sys Taiwan Lactobacillus (Lactobacillus taiwanensis) NIBRBA00501006 strain culture supernatant from these results, it was confirmed that the activity shown by the AMPs material.
실시예 6. 유기용매 분획에 의한 배양 상등액의 정제Example 6. Purification of culture supernatant by organic solvent fraction
락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주 배양 상등액 중에 포함된 물질이 AMPs 물질인지 확인하기 위해 부분 정제를 실시하였다.The substance contained in the N-Sys Taiwan Lactobacillus (Lactobacillus taiwanensis) NIBRBA00501006 strain culture supernatant was subjected to partial purification to ensure that the AMPs material.
우선 메탄올 농도에 따른 분획들에서 각 메탄올 농도에 따른 분획물 중에서 침전물들은 이전 연구에서 활성이 없는 것으로 나타났기 때문에 모두 폐기하였다. 즉, AMPs 물질들의 일반적인 특성은 50% 정도의 소수성을 나타내는 아미노산을 보유하는 것이 높은 활성을 나타내는 것으로 잘 알려져 있으므로 더 높은 소수성을 나타낼 수 있는 메탄올 분획의 침전물들은 활성이 매우 낮거나 없을 것으로 추정되었고, 실재 분석결과에서도 활성이 나타나지 않았다. First, in the fractions according to the methanol concentration, the precipitates among the fractions according to the methanol concentration were all discarded because the previous study showed no activity. That is, the general characteristics of AMPs are that it is well known that having an amino acid having hydrophobicity of about 50% exhibits high activity, so it was estimated that the precipitates of the methanol fraction capable of showing higher hydrophobicity have very low or no activity, There was no activity in the actual analysis results.
농축된 배양 상등액은 30%, 50%, 및 70% 메탄올로 유기용매 분획(organic solvent fractionation)을 수행하였다. 각 농도의 메탄올로 조정한 후, 4℃에서 1시간 반응을 하고, 2,000rpm에서 20분간 원심분리를 수행하여 상등액과 침전물을 각각 분리하였다. 침전물은 상등액과 동량의 증류수로 재현탁한 후, 원량에 대해 10배 농축하였다. The concentrated culture supernatant was subjected to organic solvent fractionation with 30%, 50%, and 70% methanol. After adjusting with each concentration of methanol, the reaction was performed at 4° C. for 1 hour, and centrifugation was performed at 2,000 rpm for 20 minutes to separate the supernatant and the precipitate, respectively. The precipitate was resuspended with the same amount of distilled water as the supernatant, and then concentrated 10 times to the original amount.
농축 후 증류수에 재현탁한 용액으로 활성을 분석해 본 결과, 도 5에 나타난 바와 같이 모든 메탄올 추출물에서 항균 활성이 존재하였고, 특히 50% 메탄올 추출물에서 가장 높은 항균 활성이 있는 것으로 나타났다(도 5 참조).As a result of analyzing the activity with a solution resuspended in distilled water after concentration, as shown in FIG. 5, antibacterial activity was present in all methanol extracts, and in particular, it was found that the highest antibacterial activity was found in 50% methanol extract (see FIG. 5).
50% 메탄올 상등액(MS50; supernatant of 50% methanol fractionation)을 에틸아세테이트와 클로로포름 용매를 사용하여 분배(partition)를 실시하였고, 각각의 물층을 수거하였다. 유기용매 층은 위 메탄올 분획에서 침전물을 제거한 것과 동일 이유에서 폐기하였다.The 50% methanol supernatant (MS50; supernatant of 50% methanol fractionation) was partitioned using ethyl acetate and chloroform solvent, and each water layer was collected. The organic solvent layer was discarded for the same reason that the precipitate was removed from the methanol fraction above.
에틸아세테이트와 클로로포름 물층은 아이스 콜드(ice cold) 0.1% TFA(trifluoroacetic acid)와 동량으로 혼합하였다. 혼합된 액은 12,000rpm에서 10분간 4℃에서 원심분리하여 침전물을 제거하였다. Ethyl acetate and chloroform aqueous layer were mixed with ice cold 0.1% trifluoroacetic acid (TFA) in the same amount. The mixed solution was centrifuged at 12,000 rpm for 10 minutes at 4°C to remove the precipitate.
수거된 상등액은 Sep-Pakⓡ plus C18 카트리지(Waters)로 로딩(loading) 하였다. 0.05% TFA로 10 베드 볼륨(bed volume)에 의해 2회 세척(washing)을 수행한 후, 0.05% TFA 용액에 10, 20, 30, 50, 및 80% ACN(acetonitrile)로 조성한 용액을 낮은 농도부터 높은 농도로 순차적으로 20ml 로딩(loading)하여 용출(elution) 하였다. 용출액(Eluted solution)은 농축을 수행하여 초발 사용된 양에 대해 최종 양이 10배 농축된 상태가 되도록 조정하였다.The collected supernatant was loaded into Sep- Pak® plus C18 cartridge (Waters). After performing two washings by 10 bed volumes with 0.05% TFA, a solution composed of 10, 20, 30, 50, and 80% ACN (acetonitrile) in 0.05% TFA solution at low concentration From then, 20ml was sequentially loaded at a high concentration and elution was performed. The eluted solution was concentrated so that the final amount was concentrated 10 times relative to the initially used amount.
50% 메탄올 상등액/클로로포름 물층과 에틸아세테이트 물층에 의한 Sep-Pak R18 용출 결과를 도 6과 7에 각각 나타내었다. 두 컬럼의 용출 결과는 모든 분획에서 항균 활성이 있는 것으로 나타났으나, FT(flowthrow)에서 가장 높은 활성을 보였다. 따라서 50% 메탄올 상등액과 FT에서 가장 높은 활성이 나타났기 때문에 본 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주 배양 상등액 중에 포함된 AMPs 물질은 친수성 및 소수성 성향을 모두 가진 펩타이드로 구성된 물질인 것으로 추정된다.Sep-Pak R18 elution results by 50% methanol supernatant/chloroform aqueous layer and ethyl acetate aqueous layer are shown in FIGS. 6 and 7 respectively. The elution results of both columns showed that all fractions had antibacterial activity, but the highest activity was shown in FT (flowthrow). Accordingly, since 50% of the methanol supernatant and the highest activity in the FT appeared AMPs substance contained in the N-Sys Taiwan Lactobacillus (Lactobacillus taiwanensis) NIBRBA00501006 strain culture supernatant is estimated to be a material composed of peptides having both the hydrophilic and hydrophobic tendencies.
실시예 7. 항균 활성 성상의 SEM 분석Example 7. SEM analysis of antimicrobial activity properties
상기 실시예 6의 방법에 의하여 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주의 조정제물에 대해 처리 시간에 따른 용균 현상을 SEM(scanning Electron Microscope)을 이용하여 관찰하였다. Lactobacillus Taiwan ensis by the method of Example 6 (Lactobacillus taiwanensis) The lysis of the NIBRBA00501006 strain according to the treatment time was observed using a scanning electron microscope (SEM).
실험은 가장 활성이 높은 Sep-Pak R18 용출물을 살모넬라 겔린아룸(Salmonella gallinarum)에 처리하고, 배양액을 0, 6, 12, 및 24 시간별로 샘플링 하였다. 샘플링된 배양액은 13,500RPM/1min 원심 분리 후, 침전물만 cover-glass에 적당량 분취한 후 알코올을 이용하여 수분 제거하고, 백금으로 코팅하여 SEM을 이용하여 관찰하였다.In the experiment, the most active Sep-Pak R18 eluate was treated with Salmonella gallinarum , and the culture was sampled at 0, 6, 12, and 24 hours. After the sampled culture was centrifuged at 13,500RPM/1min, only an appropriate amount of the precipitate was aliquoted on the cover-glass, water was removed with alcohol, coated with platinum, and observed using SEM.
그 결과, 도 8에 나타난 바와 같이 시간이 경과함에 따라 세포막에 천공(hole, 화살표에 의해 표시)이 발생되는 세균 수가 증가하는 것이 관찰되었다. As a result, as shown in FIG. 8, it was observed that the number of bacteria having holes (marked by arrows) in the cell membrane increased as time passed.
종합하면, 락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주 배양 상등액의 항균활성은 AMPs 물질에 의해 나타나며, 대상 유해 균주들의 농도에 반비례하는 반면에 항균물질의 농도에 비례하는 것으로 나타났다. 본 항균 펩타이드(AMPs)는 부분적으로 친수성(partial hydrophilic) 성향을 나타내며, 세포벽에 천공(hole)을 형성하여 용균 현상을 야기하는 것으로 나타났다.Taken together, Lactobacillus taiwanensis The antimicrobial activity of the NIBRBA00501006 strain culture supernatant was indicated by the AMPs substance, and was inversely proportional to the concentration of the target harmful strains, while it was found to be proportional to the concentration of the antibacterial substance. The antimicrobial peptides (AMPs) have been shown to show a partial hydrophilic tendency and cause lysis by forming a hole in the cell wall.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As described above, specific parts of the present invention have been described in detail, and it is obvious that these specific techniques are only preferred embodiments and are not intended to limit the scope of the present invention to those of ordinary skill in the art. Accordingly, it will be said that the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims (13)
상기 균주는 살모넬라 속 균주, 에스체리치아 속 균주, 스트렙토코커스 속 균주, 바실러스 속 균주, 및 사카로마에세스 속 균주로 구성된 군으로부터 선택되는 어느 하나 이상의 병원균에 대해 항균 활성을 갖는 것을 특징으로 하고,
상기 살모넬라 속 균주는 살모넬라 겔린아룸(Salmonella gallinarum)이고, 상기 에스체리치아 속 균주는 에스체리치아 콜라이(E. coli)이며, 상기 스트렙토코커스 속 균주는 스트렙토코커스 이니에(Streptococcus iniae)이고, 상기 바실러스 속 균주는 바실러스 세레우스(B. cereus)이며, 상기 사카로마에세스 속 균주는 사카로마에세스 세레비제(S. cerevisiae)인 것을 특징으로 하는,
락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주.The method of claim 1,
The strain is characterized by having antimicrobial activity against any one or more pathogens selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp.
The strain of the genus Salmonella is Salmonella gallinarum , the strain of the genus Escherichia is E. coli, the strain of the genus Streptococcus is Streptococcus iniae , and the The strain of the genus Bacillus is Bacillus cereus (B. cereus ), and the strain of the genus Saccharomyces is characterized in that the strain of the genus Saccharomyces is S. cerevisiae.
Lactobacillus taiwanensis NIBRBA00501006 strain.
상기 살모넬라 속 균주는 살모넬라 겔린아룸(Salmonella gallinarum)이고, 상기 에스체리치아 속 균주는 에스체리치아 콜라이(E. coli)이며, 상기 스트렙토코커스 속 균주는 스트렙토코커스 이니에(Streptococcus iniae)이고, 상기 바실러스 속 균주는 바실러스 세레우스(B. cereus)이며, 상기 사카로마에세스 속 균주는 사카로마에세스 세레비제(S. cerevisiae)인 것을 특징으로 하는,
락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주를 유효성분으로 함유하는 항균용 약학적 조성물.Deposited with the accession number KCTC 18771P, it exhibits antimicrobial activity against any one or more pathogens selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp. strain. ,
The strain of the genus Salmonella is Salmonella gallinarum , the strain of the genus Escherichia is E. coli, the strain of the genus Streptococcus is Streptococcus iniae , and the The strain of the genus Bacillus is Bacillus cereus (B. cereus ), and the strain of the genus Saccharomyces is characterized in that the strain of the genus Saccharomyces is S. cerevisiae.
Lactobacillus taiwanensis ( Lactobacillus taiwanensis ) NIBRBA00501006 Antibacterial pharmaceutical composition containing the strain as an active ingredient.
상기 살모넬라 속 균주는 살모넬라 겔린아룸(Salmonella gallinarum)이고, 상기 에스체리치아 속 균주는 에스체리치아 콜라이(E. coli)이며, 상기 스트렙토코커스 속 균주는 스트렙토코커스 이니에(Streptococcus iniae)이고, 상기 바실러스 속 균주는 바실러스 세레우스(B. cereus)이며, 상기 사카로마에세스 속 균주는 사카로마에세스 세레비제(S. cerevisiae)인 것을 특징으로 하는,
락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주를 유효성분으로 함유하는 항균용 건강기능식품 조성물.Deposited with the accession number KCTC 18771P, it exhibits antimicrobial activity against any one or more pathogens selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp. strain. ,
The strain of the genus Salmonella is Salmonella gallinarum , the strain of the genus Escherichia is E. coli, the strain of the genus Streptococcus is Streptococcus iniae , and the The strain of the genus Bacillus is Bacillus cereus (B. cereus ), and the strain of the genus Saccharomyces is characterized in that the strain of the genus Saccharomyces is S. cerevisiae.
Antibacterial health functional food composition containing the strain of Lactobacillus taiwanensis NIBRBA00501006 as an active ingredient.
상기 살모넬라 속 균주는 살모넬라 겔린아룸(Salmonella gallinarum)이고, 상기 에스체리치아 속 균주는 에스체리치아 콜라이(E. coli)이며, 상기 스트렙토코커스 속 균주는 스트렙토코커스 이니에(Streptococcus iniae)이고, 상기 바실러스 속 균주는 바실러스 세레우스(B. cereus)이며, 상기 사카로마에세스 속 균주는 사카로마에세스 세레비제(S. cerevisiae)인 것을 특징으로 하는,
락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주를 유효성분으로 함유하는 항균용 식품 보존제 조성물.Deposited with the accession number KCTC 18771P, it exhibits antimicrobial activity against any one or more pathogens selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp. strain. ,
The strain of the genus Salmonella is Salmonella gallinarum , the strain of the genus Escherichia is E. coli, the strain of the genus Streptococcus is Streptococcus iniae , and the The strain of the genus Bacillus is Bacillus cereus (B. cereus ), and the strain of the genus Saccharomyces is characterized in that the strain of the genus Saccharomyces is S. cerevisiae.
Lactobacillus taiwanensis (Lactobacillus taiwanensis) NIBRBA00501006 Antibacterial food preservative composition containing the strain as an active ingredient.
상기 살모넬라 속 균주는 살모넬라 겔린아룸(Salmonella gallinarum)이고, 상기 에스체리치아 속 균주는 에스체리치아 콜라이(E. coli)이며, 상기 스트렙토코커스 속 균주는 스트렙토코커스 이니에(Streptococcus iniae)이고, 상기 바실러스 속 균주는 바실러스 세레우스(B. cereus)이며, 상기 사카로마에세스 속 균주는 사카로마에세스 세레비제(S. cerevisiae)인 것을 특징으로 하는,
락토바실러스 타이완엔시스(Lactobacillus taiwanensis) NIBRBA00501006 균주를 유효성분으로 함유하는 항균용 사료 첨가제 조성물.Deposited with the accession number KCTC 18771P, it exhibits antimicrobial activity against any one or more pathogens selected from the group consisting of Salmonella sp. strain, Escherichia sp. strain, Streptococcus sp. strain, Bacillus sp. strain, and Saccharomyces sp. strain. ,
The strain of the genus Salmonella is Salmonella gallinarum , the strain of the genus Escherichia is E. coli, the strain of the genus Streptococcus is Streptococcus iniae , and the The strain of the genus Bacillus is Bacillus cereus (B. cereus ), and the strain of the genus Saccharomyces is characterized in that the strain of the genus Saccharomyces is S. cerevisiae.
Lactobacillus taiwanensis (Lactobacillus taiwanensis) NIBRBA00501006 Antibacterial feed additive composition containing the strain as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190060484A KR102191432B1 (en) | 2019-05-23 | 2019-05-23 | Lactobacillus taiwanensis strain having antibacterial activity against harmful bacteria and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190060484A KR102191432B1 (en) | 2019-05-23 | 2019-05-23 | Lactobacillus taiwanensis strain having antibacterial activity against harmful bacteria and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200134682A KR20200134682A (en) | 2020-12-02 |
KR102191432B1 true KR102191432B1 (en) | 2020-12-15 |
Family
ID=73780437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190060484A KR102191432B1 (en) | 2019-05-23 | 2019-05-23 | Lactobacillus taiwanensis strain having antibacterial activity against harmful bacteria and uses thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102191432B1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101750468B1 (en) | 2016-03-04 | 2017-06-27 | 주식회사 메디오젠 | Composition comprising Lactobacillus fermentum MG901 or Lactobacillus plantarum MG989 |
KR101757623B1 (en) | 2016-02-19 | 2017-07-17 | 대한민국 | Lactobacillus plantarum KCC-10 and composition comprising the same |
KR101772870B1 (en) | 2016-02-05 | 2017-08-30 | 명지대학교 산학협력단 | Novel Lactobacillus plantarum with probiotic activities and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101658377B1 (en) | 2010-02-08 | 2016-09-21 | 영남대학교 산학협력단 | Lactobacillus plantarum against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same |
-
2019
- 2019-05-23 KR KR1020190060484A patent/KR102191432B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101772870B1 (en) | 2016-02-05 | 2017-08-30 | 명지대학교 산학협력단 | Novel Lactobacillus plantarum with probiotic activities and use thereof |
KR101757623B1 (en) | 2016-02-19 | 2017-07-17 | 대한민국 | Lactobacillus plantarum KCC-10 and composition comprising the same |
KR101750468B1 (en) | 2016-03-04 | 2017-06-27 | 주식회사 메디오젠 | Composition comprising Lactobacillus fermentum MG901 or Lactobacillus plantarum MG989 |
Non-Patent Citations (4)
Title |
---|
BMC Microbiology, Vol.18, pp.1-11(2018.08.30.) |
International Journal of Systematic and Evolutionary Microbiology, Vol.59, pp.2064-2068(2009.08.01.) |
ONCOLOGY LETTERS, Vol.16, pp.7035-7047(2018.09.) |
최종보고서, ‘자생미생물자원 유래 천연 면역조절 기능성 소재 탐색(1차년도)’, (2018.11.)* |
Also Published As
Publication number | Publication date |
---|---|
KR20200134682A (en) | 2020-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102500894B1 (en) | Lactic acid bacteria and their uses | |
CN105087423B (en) | Novel Bei Laisi bacillus CJBV and the bactericidal composition containing it | |
KR102052056B1 (en) | Lactobacillus plantarum having antibacterial activity and uses thereof | |
KR100860785B1 (en) | Natural antibiotics containing a fermentation product of garlic by lactobacilli | |
US10487112B2 (en) | Pediococcus acidilactici derived antimicrobial hexapeptide and preparation method thereof | |
KR101594446B1 (en) | Bacillus subtilis RX7 strain having antimicrobial activity against harmful microorganism and uses thereof | |
KR101372200B1 (en) | Lactobacillus plantarum SY99 and Use Thereof | |
CN102071162A (en) | Bacillus subtilis LFB112 as well as bacteriocin produced by same and application thereof | |
KR102052047B1 (en) | Pediococcus pentosaceus having antibacterial activity and uses thereof | |
KR102434487B1 (en) | Vagina-derived lactobacillus rhamnosus vg.q2 strain having antimicrobial activity against microorganisms causing vaginosis and uses thereof | |
KR101068531B1 (en) | Novel bacteriocin-producing lactic acid bacteria and mixed microbial composition using it for livestocks | |
KR101865461B1 (en) | A antimicrobial peptide and a antimicrobial composition containing the same | |
KR101047948B1 (en) | Lactobacillus Producing Bacteriocin and Probiotic Composition Containing the Same | |
KR101836365B1 (en) | Kimchi seasoning containing Leuconostoc mesenteroides WiKim32 and kimchi prepared by using the same | |
KR20060108964A (en) | Enterococcus faecalis cbt-sl(5), preparation of its culture fluid and composition comprising the same | |
KR20120118570A (en) | Lactococcus lactis et45 and use thereof | |
KR20180087662A (en) | A pharmaceutical composition comprising cystatin and protein derived from lactic acid bacteria | |
KR102191432B1 (en) | Lactobacillus taiwanensis strain having antibacterial activity against harmful bacteria and uses thereof | |
KR20030064462A (en) | Novel microorganism inhibiting the growth of harmful bacteria and microbial preparation containing same as an effective ingredient | |
KR101086239B1 (en) | Novel bacteriocin-producing lactic acid bacteria and mixed microbial composition using it for broiler chickens | |
KR102191437B1 (en) | Nibribacter radioresistens strain having antibacterial activity against harmful bacteria and uses thereof | |
KR102457367B1 (en) | Lactobacillus plantarum wikim0126 strain derived from jeju pickled brussels sprout food and method for preparing composition using same | |
KR102621450B1 (en) | Novel Latilactobacillus curvatus M21F011 strain, and uses thereof | |
US20230381249A1 (en) | Probiotic strain for countering caries pathogens | |
KR102457366B1 (en) | Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |